Yudao Bio is a technology company.
Yudao Bio has raised $40.0M across 1 funding round.
Yudao Bio has raised $40.0M in total across 1 funding round.
Yudao Bio has raised $40.0M in total across 1 funding round.
Yudao Bio's investors include Genesis Capital.
Yudao Bio appears to be a biotechnology company focused on biopharmaceutical products, potentially operating in areas like drug development for unmet clinical needs, though details are sparse and may overlap with similar entities such as Shanghai Yuyao Biotechnology or Yuyao Biotech.[4][5] These related firms leverage artificial intelligence and modern drug creation technologies to target diseases like neoplasms, hemic/lymphatic disorders, and immune/endocrine conditions, with pipelines emphasizing small molecule drugs against targets like STAT3 for cancers including pancreatic and colonic.[1][3] Shanghai Yuyao Biotechnology, established in 2020, provides technology services, consulting, transfers, and promotions while building a Phase 2 drug (YY-201) to address significant clinical gaps and improve human health through AI-driven innovation and partnerships with top institutions.[1]
The company serves pharmaceutical researchers, clinicians, and patients with hard-to-treat conditions, solving problems in drug discovery for oncology and related fields by accelerating R&D via AI and translational medicine.[1][3] Growth indicators include an active pipeline with 7 small molecule projects in preclinical to Phase 2 stages, institutional collaborations, and a focus on production-education-research integration, positioning it amid rising AI-biopharma momentum.[1]
Specific founding details for Yudao Bio are limited in available records, with mentions linking it to biopharma product development without precise dates or founders.[4][5] It likely emerged from China's burgeoning biotech ecosystem, akin to Shanghai Yuyao Biotechnology Co., Ltd., formally established on April 13, 2020, in Shanghai.[1] This entity was founded to harness AI and new drug technologies amid growing demand for innovative therapies, quickly building ties with domestic research organizations for integrated advancement.[1]
Early traction for analogs includes Shanghai Yuyao's pipeline progress to Phase 2 for YY-201 (STAT3 inhibitor for pancreatic/colonic cancers) and focus on high-need areas like neoplasms (7 projects), reflecting pivotal shifts toward AI-guided discovery post-2020 biotech funding booms in China.[1][3] No named founders are detailed, but the model's emphasis on tech transfer and consulting suggests origins in academic or institutional expertise.
Yudao Bio rides the AI-biopharma convergence trend, where machine learning accelerates drug design for complex diseases like cancer, aligning with global pushes in precision medicine.[1][3] Timing is ideal amid China's biotech investments and post-2020 AI adoption, fueled by market forces like aging populations, rising oncology burdens, and regulatory support for innovative therapies.[1] It influences the ecosystem by promoting tech transfers and institutional partnerships, fostering domestic innovation hubs that reduce reliance on Western pipelines and integrate AI into clinical translation.[1]
Yudao Bio is poised for pipeline milestones, potentially advancing YY-201 to later trials and expanding AI tools for more indications, driven by China's biopharma growth.[1] Trends like AI-optimized small molecules and global oncology demand will shape its path, with influence evolving through deeper collaborations and possible international deals. As an early-stage player in AI-drug discovery, it could redefine accessible therapies, circling back to its core mission of tackling unmet clinical needs with tech precision.[1][3]
Yudao Bio has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $40.0M Series A | Genesis Capital |